Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 21, 2018
Pharmacy Choice - News - Pharmaceutical Development - March 21, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/21/17 - 10 Stocks To Watch For December 21, 2017
Conagra shares gained 1.21 percent to $38.60 in after-hours trading. Analysts expect Nike Inc to post quarterly earnings at $0.4 per share on revenue of $8.39 billion after the closing bell. Nike shares declined 1.01 percent to close at $63.59 on Wednesday. Allergan plc reported that the FDA has accepted NDA for Seysara for treatment of moderate to
12/21/17 - 3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018 [Algeria Press Service]
Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. Immuno-oncology was a key focus area in 2017, whether it was to do with scientific conferences, clinical trial collaborations, acquisitions or FDA approvals. The $11.9 billion acqui
12/21/17 - 35 Stocks Moving In Thursday's Pre-Market Session
Gainers AEterna Zentaris Inc. rose 69.1 percent to $3.39 in pre-market trading after the company reported the FDA approval of Macrilen for diagnosis of adult growth hormone deficiency. Net Element International Inc rose 50.6 percent to $29.20 in the pre-market trading session following Wednesday announcement of Blockchain business unit. NXT-ID Inc.
12/21/17 - 36 Stocks Moving In Thursday's Mid-Day Session
LexinFintech priced its IPO at $9 per share. JetPay Corporation shares gained 62.5 percent to $4.305 as traders circulate a comparison article of JetPay versus BitPay. AEterna Zentaris Inc. shares jumped 44 percent to $2.89 after the company reported the FDA approval of Macrilen for diagnosis of adult growth hormone deficiency. Net Element Internat
12/21/17 - 60P Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
Washington DC- 60 Degrees Pharmaceuticals announced it has submitted a New Drug Application to the United States Food and Drug Administration for the use of Tafenoquine to prevent malaria in adults traveling to areas where malaria is prevalent. Malaria, a life-threatening disease caused by Plasmodium parasites that are transmitted to people through
12/21/17 - 62% of US Respondents Want Their Cancer Genetically Tested to Find New Treatments: Wamberg Genomic Survey
Survey Sampling International fielded the survey in October/ November 2017. Phil Smalley, Chief Medical Director of Wamberg Genomic Advisors has noted that in recent reports 3 the benefits of cancer genomic profiling include:. Tom Wamberg, CEO of Wamberg Genomic Advisors said, "It is encouraging to see in our recent survey the degree to which the p
12/21/17 - Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB [T-break Tech (Middle East)]
-Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today that the first patient in a Phase 1/ 2 clinical trial for ABO-101, a single treatment gene therapy for patients with Sanfilippo syndrome type B, has been dosed at Natio
12/21/17 - ADVAXIS, INC. - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations.
This Management's Discussion and Analysis of Financial Conditions and Results of Operations and other portions of this report contain forward-looking information that involves risks and uncertainties. Overview Advaxis, Inc. is a late-stage biotechnology Company focused on the discovery, development and commercialization of proprietary Lm...
12/21/17 - Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug [Arab Times (Kuwait)]
Aerie Pharmaceuticals` Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to prostaglandin analogues. There are 60 million cases of glaucoma worldwide, and according to the World Health Organization, glaucoma is the second leading reason why peo
12/21/17 - AEterna Dazzles on Receiving FDA Approval
AEterna Zentaris Inc. moved skyward Thursday after the company reported the FDA approval of Macrilen for diagnosis of adult growth hormone deficiency. The Company estimates that approximately 60,000 tests for suspected AGHD are being conducted each year across the United States, Canada and Europe. In the absence of an FDA- approved diagnostic te
12/21/17 - Allergan's VISTABEL Receives Positive Opinion from ANSM for Treatment of Moderate to Severe Forehead Lines in Adult Patients in 30 European Countries
DUBLIN, IRELAND- Allergan plc, a global biopharmaceutical company, today announced that VISTABEL has received a Positive Opinion from the Agence Nationale de Securite du Medicament et des Produits de Sante for the temporary improvement in the appearance of moderate to severe forehead lines in adults when the severity of the facial lines has an impo
12/21/17 - Allergan: FDA Accepts NDA For Acne Drug Seysara
WASHINGTON- Allergan plc, and Paratek Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted New Drug Application to review Seysara for moderate to severe acne vulgaris in patients 9 years of age and older. Allergan has U.S. rights to the development and commercialization of Seysara. Allergan owns the U.S. rights to
12/21/17 - Altimmune Announces Positive Initial Data from Its HepTcell Phase 1 Study
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced it has completed dosing of its HepTcell Phase 1 study in chronic hepatitis B. All doses were well tolerated, there were no hepatic flares, and no discontinuations. Additionally, the preliminary data showed evidence of dose dependent increases in cellular immune response
12/21/17 - Ambrx and TRACON Pharmaceuticals Announce Development and Commercialization Agreement for TRC105 in China
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age related macular degeneration and fibrotic diseases, and Ambrx, Inc., today announced that they have entered into a licensing agreement for the development and commercialization o
12/21/17 - Amphastar Announces Approval for Sodium Nitroprusside Injection, USP
RANCHO CUCAMONGA- Amphastar Pharmaceuticals, Inc., announced that today the U.S. Food and Drug Administration granted approval of its abbreviated new drug application for Sodium Nitroprusside Injection 25 mg/mL, 2 mL single dose vial, indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crisis.
12/21/17 - Analyst: La Jolla Pharma A Buy Ahead Of February FDA Date
La Jolla Pharmaceutical Company has an upcoming catalyst in the form of a Feb. 28 PDUFA date. Wainwright analyst Edward White initiated coverage of the shares of La Jolla with a Buy rating and a $62 price target. With the company having submitted the NDA for LJPC-501 a treatment candidate for vasodilatory shockm to the FDA, the PDUFA date is se
12/21/17 - Array BioPharma Announces Strategic Collaboration with Pfizer
BOULDER- Array BioPharma announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array's MEK inhibitor, binimetinib, with Pfizer's investigational PARP inhibitor talazoparib, and avelumab, a human anti-PD-L1 IgG1...
12/21/17 - Asklepion Pharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Program of Intravenous Citrulline
Gary R. Pasternack, MD, PhD, Chief Executive Officer of Asklepion Pharmaceuticals, stated' This SPA confirms the ongoing collaborative discussion Asklepion has had with the Agency and we would like to thank the FDA for its invaluable guidance throughout this process. A Special Protocol Assessment from the FDA is a special procedure by which the FDA
12/21/17 - AstraZeneca snags speedy Tagrisso review in first-line EGFR lung cancer patients [Syrian Arab News Agency]
And now, the FDA is helping the drug speed toward an approval in that population. Tagrisso has picked up the agencys priority review tag, AstraZeneca said on Thursday, based on results from the British companys phase 3 Flaura trial. Those results showed Tagrisso could cut the risk of disease progression or death in first-line, EGFR patients by 54%
12/21/17 - Backed by Dana-Farber Research, FDA Approves New Indication for a Kidney Cancer Drug
The Dana-Farber Cancer Institute issued the following news release:. A targeted drug whose clinical testing was led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, has become a standard first-line therapy for certain newly diagnosed patients with advanced kidney cancer. The drug, cabozantinib, was approved today by the U.S. Food and Drug.
12/21/17 - Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers [Syrian Arab News Agency]
Bayer today announced that its collaboration partner Loxo Oncology, Inc., has initiated the submission of a rolling New Drug Application to the U.S. Food and Drug Administration for larotrectinib. Bayer and Loxo Oncology are jointly developing larotrectinib, an investigational compound being studied globally for the treatment of patients with cance
12/21/17 - Beckman Coulter Diagnostics receives FDA clearance for the automated Access AMH Immunoassay to benefit fertility patients
Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use in the U.S. This simple test aids healthcare providers in the assessment of a woman's ovarian reserve, and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.
12/21/17 - Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
CAMBRIDGE, Mass.& CARLSBAD- Biogen and Ionis Pharmaceuticals, Inc. announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy. 'We are pleased to extend our collaboration with our valued colleagues at Ionis, which we believe complem
12/21/17 - Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, today announced that it has commenced enrollment in its Phase 2/ 3 clinical trial assessing the efficacy and safety of trigriluzole in patients with...
12/21/17 - BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today initiation of the Phase 3 GENESIS clinical trial, in which BL-8040 will be compared to placebo, on top of granulocyte colony-stimulating factor, for the mobilization of hematopoietic stem cells used for autologous transplantation in multip
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement